Strategic Areas of Focus
Scientific and strategic support designed to bridge the structural gap between data generation and defensible, decision-ready evidence.
I design translational safety strategies that connect nonclinical evidence to first-in-human dose selection and early protocol design. Rather than simply identifying risks, I anticipate signal emergence and interpretation — enabling efficient early-phase learning without unnecessary interruption.
Fractional Safety Leadership
CMO-level advisory as a fractional senior safety leadership option, providing strategic oversight without full-time role overhead.
Credibility in drug development is built one defensible decision at a time.
Let’s Discuss Your Challenge